Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is somewhat busy. We plan to escort Mrs. Pharmalot to yet another installment in our “Let’s-see-them-before-they-die” concert series, accompany our short people to our favorite deli and celebrate National Coffee Day, although every day is National Coffee Day on the Pharmalot campus. But what about you? Autumn is in full swing, so this remains an opportunity to pick some apples. You could even make your own cider. Conversely, you could spend time indoors and winterize your castle. Or you could leaf through your high school calendar and reflect on the past. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …

Eli Lilly (LLY) won U.S. regulatory clearance for a new migraine drug that will be the third in a promising class of therapies, STAT tells us. The Food and Drug Administration approved Emgality, a CGRP inhibitor that Lilly will offer at no cost for a year to millions of patients with commercial insurance, a move that reflects increased scrutiny of high prescription costs in the U.S. and fierce competition in a hot treatment area. In this way, Lilly will be able to ensure patients are getting its medication even as insurers finalize coverage or reimbursement policies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!